血清Corin水平对非ST段抬高急性冠脉综合征预后的意义

The prognosis prediction value of serum corin in patients with non-ST-elevation acute coronary syndrome

目的:明确丝氨酸蛋白酶Corin在急性冠脉综合征患者中的水平变化及其作为预后标志物的临床意义.方法:本研究共纳入2010-12/2014-12受试对象255名,其中进行经皮冠脉介入(PCI)的非ST抬高急性冠脉综合征患者152名,对照健康体检人员103名.采用酶联免疫吸附法(ELISA)对丝氨酸蛋白酶Corin的水平进行检测.结果:丝氨酸蛋白酶Corin在急性冠脉综合征患者中的水平要显著低于对照组患者(798±288 pg/m L vs 1165±613 pg/m L,P<0.05).丝氨酸蛋白酶Corin在发生主要心血管事件的急性冠脉综合征患者中的水平要显著低于未发生急性冠脉综合征的患者(698.16±233.67 pg/m L vs 952.1±297.81 pg/m L,P<0.05).经多元逻辑回归分析显示Corin的水平是急性冠脉综合征PCI术后发生主要心血管事件的显著预测子(P<0.05).结论:非ST段抬高急性冠脉综合征患者和发生主要心血管事件的急性冠脉综合征患者的血清Corin水平都呈现显著降低的趋势.在急性冠脉综合征的患者中,Corin可能可以作为一种新型的生物标记物独立或联合其他生物标记物用于心血管事件分类评价及临床结果预测.

AIM: To investigate the level of serine protease corin and its role in prognosis prediction in patients with acute coronary syndrome ( ACS) . METHODS:A total of 255 subjects were included in this study, including 152 ACS patients who underwent percutaneous coronary intervention and 103 control subjects. The serum corin level of all these subjects were measured by enzyme?linked immunoabsorbent assay. RESULTS:The corin level was significantly lower in ACS patients than in the controls ( 798 ± 288 pg/mL vs 1165 ± 613 pg/mL, P<0. 05 ) . A significantly lower corin level was also observed in ACS patients who developed major adverse cardovascular events ( MACE) than those who did not experience major adverse cardiovascular events (698.16±233.67 pg/mL vs 952.1±297.81 pg/mL, P<0.05). Using a multiple logistic regression model, corin level was a predictor of post?ACS MACE (P<0.05). CONCLUSION: The serum corin levels of patients with non?ST?elevation ACS and those who encountered major adverse cardiovascular events decreased significantly. In ACS patients, corin, as a novel biomaker, could be used either alone or in combination with other biomarkers for cardiovascular risk stratification assessment and outcome prediction.